Stay updated with breaking news from Scott Plevy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively.NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Compan...
New England Journal of Medicine Publishes Efficacy and Safety Data ...
PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and...
/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!